POTENTIAL DEAL DETAILS
|Stock||Genetron Holdings Limited||Symbol||GTH|
|Date Announced||08/22/2022||Source||Press Release|
|Type||Unsolicited Bid||Acquiring Company/Person||Sizhen Wang, co-founder, chairman of the Board and chief executive officer|
Genetron Holdings Limited (GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products, and companion diagnostics development, announced that its Board of Directors has received a preliminary non-binding proposal letter dated August 21, 2022, from Sizhen Wang, co-founder, chairman of the Board and chief executive officer of the company to acquire all of the outstanding ordinary shares, par value $0.00002 per share of the Company, including the Ordinary Shares represented by the American depositary shares of the Company (the “ADSs”, each representing five Ordinary Shares) for US$0.272 per Ordinary Share or US$1.36 per ADS in cash.
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.